Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin liposomal - Imunon

Next Previous
X
Search
Drug Profile

Doxorubicin liposomal - Imunon

Alternative Names: Liposome encapsulated doxorubicin; LTLD; LTSDEL; Lyso-thermosensitive liposomal doxorubicin; ThermoDox

Latest Information Update: 28 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celsion Corporation
  • Developer Brigham and Womens Hospital; Harvard Medical School; Imunon; National Institute for Health Research; Oxford University Hospitals NHS Trust; University of Oxford; Utrecht University
  • Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Liver cancer
  • Phase II Breast cancer; Colorectal cancer; Liver metastases
  • No development reported Bladder cancer; Brain cancer; Glioblastoma; Pancreatic cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for clinical-Phase-Unknown development in Bladder-cancer(Combination therapy) in USA (IV)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Late-stage disease, Metastatic disease) in United Kingdom (IV, Liposomal)
  • 28 Apr 2023 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease) in Netherlands (IV, Liposomal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top